No widely used medication has been definitively proven to cause pancreatic cancer in the way that, say, smoking or heavy alcohol use raises risk. But a growing body of research has flagged several drug classes as potentially associated with higher pancreatic cancer incidence, and the picture is complicated by the fact that the diseases those drugs treat (especially diabetes) are themselves strong risk factors. The drugs that generate the most concern include certain diabetes medications, long-term acid-suppressing drugs, and immunosuppressants, while others like metformin and aspirin appear to push risk in the opposite direction. Sorting genuine drug effects from the noise of underlying disease turns out to be one of the hardest problems in cancer epidemiology.
Insulin and Drugs That Boost Insulin Secretion
The strongest and most consistent signal linking a drug class to pancreatic cancer comes from insulin itself and from medications that push the pancreas to release more of it. A large case-control study found that people with diabetes who had used insulin or insulin-stimulating drugs (called secretagogues, which include older sulfonylurea pills like glipizide and glyburide) had a significantly higher risk of pancreatic cancer than diabetics who had not taken those drugs.1PubMed Central. Anti-diabetic therapies affect risk of pancreatic cancer The biological logic is straightforward: insulin is a growth-promoting hormone, and pancreatic tissue that sits right next to insulin-producing cells gets bathed in especially high local concentrations of it. More insulin means more growth signaling, and in cells that already have early damage, that extra push could accelerate a slide toward cancer.
That said, untangling the drug effect from the disease effect is tricky. Type 2 diabetes itself roughly doubles the risk of pancreatic cancer, and people who need insulin or strong secretagogues tend to have more advanced or longer-standing diabetes. A review of both clinical and lab evidence concluded that insulin appears safe for people with long-standing diabetes but may increase pancreatic cancer risk specifically in high-risk populations.2Frontiers in Cell and Developmental Biology. The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular In other words, the drug is not necessarily dangerous on its own, but it may amplify an existing vulnerability.
Metformin as a Counterexample
If insulin and secretagogues raise concern, metformin does the opposite. Multiple analyses have found that people with type 2 diabetes who take metformin have a lower risk of pancreatic cancer compared to those on other diabetes drugs. A systematic review and meta-analysis reported roughly a 20% reduction in pancreatic cancer risk among metformin users compared with users of other glucose-lowering medications.3PubMed Central. The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis An earlier meta-analysis found a larger reduction, putting the risk at about 37% lower for metformin users.4Diabetes Research and Clinical Practice. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
One Taiwanese population study of roughly 800,000 individuals found an even more dramatic association: after adjusting for other diabetes medications, metformin use was linked to a dramatically lower pancreatic cancer incidence.5PubMed Central. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals Metformin works differently from most diabetes drugs. Rather than pushing the pancreas to make more insulin or injecting insulin directly, it makes the body more sensitive to the insulin already there and dampens glucose production in the liver. It also activates a cellular energy sensor that tends to slow cell growth. That dual action may explain why metformin keeps appearing as protective in study after study. For anyone with diabetes who worries about pancreatic cancer, metformin’s track record is unusually reassuring.
GLP-1 Receptor Agonists and DPP-4 Inhibitors
Few drug-cancer questions have generated more debate in the past decade than whether the newer “incretin-based” diabetes and weight-loss drugs raise pancreatic cancer risk. This class includes GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), liraglutide, and exenatide, as well as DPP-4 inhibitors (sitagliptin, saxagliptin, and others). Early animal experiments raised alarm: mice treated with exenatide showed increased cell proliferation in pancreatic ducts and changes in pre-cancerous lesions that looked like they were progressing faster.6npj Gut and Liver. Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy Safety signals also popped up in adverse event databases in the United States and Europe.7PubMed. GLP1 and cancer: friend or foe?
The pharmacovigilance data looked especially dramatic. An analysis of the FDA’s adverse event reporting system found thousands of pancreatic cancer reports linked to GLP-1 receptor agonists, with liraglutide and exenatide showing the strongest reporting signals and semaglutide and dulaglutide showing weaker ones.8PubMed. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis A broader pharmacovigilance study confirmed signals for several GLP-1 analogues and DPP-4 inhibitors among the small number of non-cancer drugs flagged for pancreatic cancer reports.9PubMed. Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology
But adverse-event databases have well-known limitations. Reports flood in once a safety concern becomes public, creating a self-reinforcing feedback loop. When researchers moved to more rigorous designs, the picture shifted. A large observational study comparing GLP-1 receptor agonists head-to-head with basal insulin found no increased pancreatic cancer risk from the fifth year onward; if anything, the point estimates favored the GLP-1 group.10PubMed Central. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes A comprehensive review of both preclinical and clinical evidence concluded that while animal studies suggest a plausible biological pathway, this concern is not supported by larger and more systematic analyses of human data.6npj Gut and Liver. Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
DPP-4 inhibitors carry a related concern. One study using sophisticated methods to account for biases estimated that combination therapy adding a DPP-4 inhibitor to metformin was associated with a somewhat higher seven-year pancreatic cancer risk compared to metformin alone.11Clinical Epidemiology. Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database The absolute risk remained low in both groups, but the finding underscores that the question is not fully settled, especially for long-term use spanning a decade or more.
Proton Pump Inhibitors
Proton pump inhibitors, the acid-blocking drugs millions of people take for heartburn and reflux, have also drawn scrutiny. A large French nationwide study found that ever using PPIs was associated with a small but statistically significant increase in pancreatic cancer risk, and the association grew stronger with cumulative use: people who had taken the highest doses over time had roughly an 18% higher risk compared to never-users.12PubMed Central. Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case–Control Study Based on the French National Health Data System (SNDS) A separate study confirmed that longer cumulative PPI use was associated with higher pancreatic cancer risk after adjusting for diabetes, smoking, alcohol, and body weight.13PubMed Central. Proton pump inhibitors on pancreatic cancer risk and survival
The proposed mechanism involves a hormone called gastrin. When you suppress stomach acid, the body compensates by ramping up gastrin production, and gastrin receptors are found on pancreatic cells. Chronically elevated gastrin could theoretically promote cell growth. But there is a major caveat: people who take PPIs for years tend to have other risk factors too, including obesity, alcohol use, and diets linked to reflux. Reverse causation also complicates things, since early pancreatic cancer can cause vague abdominal symptoms that get treated with PPIs before the cancer is diagnosed. The absolute increase in risk, if real, is modest. Still, for people who have been on a PPI for years without a clear ongoing need, this data adds to the reasons clinicians suggest periodic reassessment.
Immunosuppressants After Organ Transplantation
People who receive organ transplants take immunosuppressive drugs for life, and their cancer risk across many types goes up. Pancreatic cancer is no exception. A study of transplant recipients in the United States found that their pancreatic cancer incidence was about 40% higher than in the general population. The increase was most pronounced among liver transplant recipients, who had roughly 65% higher incidence.14PubMed Central. Pancreatic cancer among solid organ transplant recipients in the United States Pancreatic cancers in transplant recipients were also more likely to be caught at an earlier, localized stage, which may reflect the closer medical surveillance these patients receive rather than a different biology.
The drugs used vary (tacrolimus, cyclosporine, mycophenolate, and others), and research has not isolated which specific immunosuppressant drives the risk most. The leading theory is that weakened immune surveillance allows pre-cancerous cells that would normally be eliminated to persist and progress. This is a population where the benefit of immunosuppression clearly outweighs the risk, but it does mean that transplant recipients and their doctors should keep pancreatic cancer in the broader picture of cancer screening.
Cardiovascular and Cholesterol Drugs
Blood pressure and cholesterol medications are among the most widely prescribed drugs on the planet, so even a tiny effect on pancreatic cancer risk would matter at the population level. The evidence here is a patchwork of reassurance and occasional concern, depending on the drug class.
Calcium channel blockers, a common class of blood pressure pills, initially raised some eyebrows. One Danish study of patients with chronic pancreatitis suggested that calcium channel blocker users might have elevated pancreatic cancer risk, though the estimates were imprecise.15PubMed Central. Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study However, a larger population-based study specifically designed to test this question found no increased risk for dihydropyridine calcium channel blockers compared to thiazide diuretics after a median follow-up of over four years.16PubMed Central. Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study
Drugs that target the renin-angiotensin system (ACE inhibitors and angiotensin receptor blockers, commonly prescribed for high blood pressure and heart failure) may actually be protective. A recent study comparing these drugs head-to-head with calcium channel blockers in older adults found a substantial reduction in pancreatic cancer risk among the renin-angiotensin drug users.17PubMed. Renin-angiotensin-aldosterone system inhibitors and risk of pancreatic cancer in older adults: A target trial emulation This is intriguing biologically because angiotensin II promotes inflammation and tissue remodeling in the pancreas, so blocking that pathway could plausibly slow cancer development.
Statins present a mixed but broadly reassuring picture. A large case-control study found that long-term statin use (over ten years) was associated with roughly half the risk of pancreatic cancer, an effect that was strongest in men.18PubMed Central. Statin use and risk of pancreatic cancer: Results from a large clinic-based case-control study Preclinical work supports this: statins have shown antitumor effects in pancreatic cancer cell lines and delayed the progression of pre-cancerous lesions in animal models.19PubMed Central. Statins and pancreatic cancer However, one Japanese population study complicated the narrative by finding that long-term use of anti-cholesterol drugs (over five years) was associated with an increased risk of pancreatic cancer in that cohort.20Scientific Reports. Long-term use of anti-cholesterol drugs and cancer risks in a Japanese population Whether this reflects a real effect in that population, confounders related to metabolic syndrome, or something else entirely remains unclear. The weight of evidence leans toward statins being neutral or mildly protective, but the Japanese finding is a reminder that population-specific factors can shift the picture.
Aspirin and NSAIDs
Aspirin stands out as one of the few commonly used drugs with fairly consistent evidence of a protective association against pancreatic cancer. A meta-analysis of observational studies found that aspirin use was linked to a roughly 23% reduction in pancreatic cancer incidence, with the benefit strongest among frequent users.21Scientific Reports. Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies A case-control study found an even larger association, with regular aspirin users having about half the risk.22PubMed Central. Case-control Study of Aspirin Use and Risk of Pancreatic Cancer And in the Women’s Health Initiative, a large prospective cohort, consistent aspirin use was associated with roughly a third lower pancreatic cancer risk, with a particularly strong protective association among women with diabetes.23PubMed Central. Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
The mechanism likely involves aspirin’s anti-inflammatory effects, specifically its ability to suppress an enzyme that drives chronic inflammation in the tissue surrounding pancreatic tumors. The interesting wrinkle is that non-aspirin NSAIDs like ibuprofen and naproxen do not seem to share this benefit. Both the meta-analysis and the Women’s Health Initiative data found no association between non-aspirin NSAIDs and pancreatic cancer risk.21Scientific Reports. Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies This suggests aspirin’s protection comes from something beyond generic anti-inflammatory action, possibly its unique and irreversible effects on platelets or its influence on specific signaling pathways that other NSAIDs do not share.
Hormone Therapies and Oral Contraceptives
Hormone-related drugs have been studied in relation to pancreatic cancer because the disease shows a slight male predominance, hinting that sex hormones might be involved. The evidence for hormone replacement therapy in postmenopausal women is fairly encouraging. A population-based matched cohort study found that ever-users of menopausal hormone therapy had a roughly 23% lower risk, and the reduction grew to about 60% in women who used it for three or more years.24PubMed Central. Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study A study using the US National Inpatient Sample found a similar direction, with women on HRT having about 31% lower odds of pancreatic cancer.25PubMed Central. Hormone replacement therapy and risk of pancreatic cancer in postmenopausal women: Evidence from the US National Inpatient Sample 2008–2018
Oral contraceptives are more ambiguous. A meta-analysis found a small overall reduction in pancreatic cancer risk associated with ever-use of oral contraceptives, though duration of use did not clearly matter.26PubMed Central. Association between oral contraceptive use and pancreatic cancer risk: A systematic review and meta-analysis A Danish cohort study of nearly two million premenopausal women found no meaningful association in any direction, regardless of type or duration of hormonal contraception.27PLOS ONE. Hormonal contraceptive use and risk of pancreatic cancer—A cohort study among premenopausal women But a wrinkle emerged from the NIH-AARP Diet and Health Study, which found that among younger women, long-term oral contraceptive use was associated with a moderately increased pancreatic cancer risk.28American Journal of Epidemiology. Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study The conflicting results suggest that age at use, formulation differences across decades, and underlying population characteristics all play a role, and no strong conclusion is warranted in either direction for oral contraceptives specifically.
Why These Studies Are So Hard to Get Right
Almost every drug-pancreatic cancer association comes with an asterisk, and the reason is a set of stubborn methodological problems that are especially severe for this cancer. Pancreatic cancer has a long latency period: it may develop silently for a decade or more before it causes symptoms. This means that when you look at what drugs a patient was taking in the years before diagnosis, you might be seeing prescriptions that were actually prompted by the cancer itself.
This is called protopathic bias (or reverse causation). Someone with undiagnosed pancreatic cancer might develop new-onset diabetes and be started on insulin, making it look like insulin caused the cancer when the cancer actually caused the diabetes. Similarly, vague abdominal pain from a growing tumor might lead a doctor to prescribe a PPI for suspected acid reflux. Researchers have tried to address this by building in “lag periods,” ignoring prescriptions from the year or two before diagnosis on the assumption that those may be contaminated by early cancer symptoms.29PubMed. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study But choosing the right lag window is more art than science, and no single approach can fully eliminate the problem.
Confounding by indication is the other major headache. People who take insulin are sicker than people who take metformin. People who take PPIs are more likely to be obese and to drink alcohol. Transplant recipients are immunosuppressed for reasons that themselves affect cancer risk. Statistical adjustments help, but they can only account for factors that researchers think to measure. The cleanest answers would come from randomized trials, but no ethics committee would approve a decades-long trial randomizing people to drugs specifically to see if they develop pancreatic cancer. So we are stuck making the best inferences we can from observational data, which is why results sometimes conflict and why caution in interpretation is essential.
Other Drugs That Have Raised Signals
Beyond the major categories, scattered signals exist for a handful of other medications. Ranitidine, the once-popular heartburn drug pulled from the market in 2020 because of a cancer-causing contaminant (NDMA), appeared in a pharmacovigilance analysis as one of the non-cancer drugs flagged for pancreatic cancer reports.9PubMed. Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology Whether the signal reflects the drug itself, the NDMA contamination, or simply the fact that people with early pancreatic symptoms take antacids remains unclear.
The same pharmacovigilance study also flagged several less commonly known drugs: fondaparinux (a blood thinner), naldemedine (an opioid-induced constipation drug), daprodustat (an anemia drug), megestrol acetate (a synthetic hormone used in cancer and appetite stimulation), leuprorelin (a hormone-suppressing drug used in prostate cancer), and lorcaserin (a weight-loss drug already withdrawn for cancer concerns).9PubMed. Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology These are signals, not verdicts. A pharmacovigilance signal means the drug was reported alongside pancreatic cancer more often than expected, but reporting biases, confounders, and the conditions being treated all muddy the water. None of these drugs has been established as a cause of pancreatic cancer through controlled studies.
TNF-alpha inhibitors, the biologic drugs used for conditions like rheumatoid arthritis and Crohn’s disease, have prompted general concern about malignancy since their introduction. Case reports of various cancers following anti-TNF therapy have accumulated over the years, though whether these drugs increase overall cancer risk or simply treat populations already at higher baseline risk remains debated.30PubMed Central. TNF-α inhibitors: are they carcinogenic? Pancreatic cancer specifically has not emerged as a standout concern in this drug class, with most attention focused on lymphoma and skin cancers.
What Truly Matters for Your Risk
If you are taking any of the medications discussed here and feeling uneasy, some perspective helps. Pancreatic cancer is relatively rare, affecting roughly 13 out of every 100,000 people per year. Even a drug that doubles a rare risk still leaves it uncommon. And many of the associations described above involve increases of 20 to 40%, not doublings. Meanwhile, the proven major risk factors for pancreatic cancer are things you may have more control over: smoking (which roughly doubles to triples risk), obesity, heavy alcohol use, chronic pancreatitis, and family history. Diabetes itself is a significant risk factor, which is precisely why the diabetes drug data is so tangled.
For most people, the benefit of their medications far outweighs any speculative pancreatic cancer risk. Nobody should stop taking insulin, a PPI, or an immunosuppressant based on epidemiological associations that remain uncertain. What the evidence does support is periodic medication review: if you have been on a PPI for years without reassessing whether you still need it, or if you are on a diabetes regimen that could be optimized with metformin, those are conversations worth having with your doctor for multiple reasons, pancreatic cancer being just one small piece of the puzzle.